Homologous booster immunization can induce the production of cross-neutralizing antibodies against 2019-nCoV variants

The Omicron variant has become the main epidemic strain in the new wave of epidemics in the world, and cases of Omicron have also been reported in China.
Vaccination is still the main preventive measure to control infectious diseases
.

At present, there are two main ways of boosting immunization, homologous booster immunization and sequential booster immunization.
The difference between the two methods is that sequential immunization is the vaccination of vaccines of different technical routes according to a certain vaccination time interval and doses.
Considering safety at the same time, an immunization strategy was adopted to further improve the preventive effect
.

For example, all target groups over 18 years old who have been vaccinated with Sinopharm Zhongsheng Beijing Company, Wuhan Company, Beijing Kexing Company's inactivated vaccine, and Tianjin CanSino Company's adenovirus vector vaccine for 6 months can receive one dose at the same time.
Source booster immunization, that is, boosting with the original vaccine
.

After the implementation of the sequential booster immunization strategy, the target population who has completed the whole process of inoculation with the above three inactivated vaccines can also choose the recombinant protein vaccine of Zhifeilong Kema or the adenovirus vector vaccine of CanSino for sequential booster immunization
.

In the face of the constant mutation of the new coronavirus, what is the protective effect of homologous enhanced immunity? Focusing on this problem, the new crown epidemic research team of the Institute of Medical Laboratory Animals, Chinese Academy of Medical Sciences immediately carried out research on whether homologous immunity of vaccines has a cross-protective effect on mutant strains
.

The rhesus monkeys were designed to be divided into two groups, vaccinated with inactivated vaccine (PiCoVacc) or recombinant protein vaccine (Anhui Zhifei Longcom Biopharmaceutical), respectively.
By detecting neutralizing antibodies, different types of homologous booster immunization strategies were evaluated against the original virus strain (Wh -09), Delta and Omicron, and monitored neutralizing antibody levels in 6 volunteers who completed 3-shot homologous booster immunizations with inactivated vaccines
.

Figure 1 The results of the animal experiments of the homologous booster immunization strategy showed that after 1 month and 3 months after the homologous booster 3 doses of inactivated vaccine, the Wh-09 (wild virus strain) group, Delta Neutralizing antibodies of mutant virus strains and Omicron mutant virus strains; 1 month and 3 months after application of homologous booster 3-injection recombinant protein vaccine, the same can be detected in serum against Wh-09 (wild virus strain) group, Neutralizing antibodies of Delta variant strain, Omicron variant strain
.

One month after the volunteers were boosted with 3 doses of inactivated vaccine, neutralizing antibodies against the Omicron variant could be detected in the serum
.

Figure 2 Neutralizing antibody titers in serum against different new coronavirus strains in rhesus monkeys who completed three doses of inactivated vaccine at 1 month and 3 months Figure 3 Six volunteers who completed 3 doses of inactivated vaccine booster immunization In summary, the vaccine homologous booster immunization strategy can significantly increase the antibody and have a cross-protection effect on different mutants.
The data in this paper suggest that the neutralizing antibodies of the whole virus inactivated vaccine are directed against different mutants.
Cross-titer is better than recombinant protein vaccine
.

This study preliminarily discusses the booster immunization strategy of homologous vaccines.
On this basis, the team has carried out in-depth sequential strategy research.
Readers can continue to pay attention to the research progress of the team
.

Don't panic when the new crown arrives, get vaccinated to protect your health; homologous immunization and sequence, build a safety line for epidemic prevention! Cite the reference LvQ, Zhou S, Qi F, Zhang Y, Li F, Liu M, Bao L.
Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants.
Animal Model Exp Med.
2022 Feb;5(1) :89-93.
doi: 10.
1002/ame2.
12216.
PMID: 35213787 Scan to read the full text About the journal AMEM is an international, open-access English-language journal co-sponsored by the Chinese Society of Laboratory Animals and the Institute of Medical Laboratory Animals, Chinese Academy of Medical Sciences , published in cooperation with the internationally renowned publishing group Wiley
.

The journals have been successively included in ESCI, MEDLINE, PMC, DOAJ and other databases, and their influence has been recognized internationally
.

The authors, readers and reviewers of the journal are from the United States, Australia, Germany, Japan, Brazil, France, Israel and other countries, showing a good international situation
.

The journal brand positioning is accurate
.

Since its inception in 2018, a total of 172 papers have been published
.

The published papers not only have the professional characteristics of experimental animal models, but also have the characteristics of significant interdisciplinary integration
.

In 2018, 2019 and 2020, the citation frequency of each article was 6.
543, among which the TOP10 cited articles are as follows
.

In 2022, AMEM will continue to strive for the right to publish excellent papers.
For high-quality manuscripts, APC will be completely exempted
.

At the same time, a 50% discount will be applied to the following article types, including Short communication, Technical note, Practice and policy, Meeting report, and AFLAS Focus and Laboratory Animal Welfare and Ethics
.

In addition, in 2022, the journal will continue to promote the construction of academic frontiers and research hotspot columns.
The column submissions include but are not limited to the following directions: (1) Research on the mechanism of action of natural medicines; (2) Research on human symbiotic microorganisms; (3) Heart and brain Vascular disease; (4) Central nervous system disease; (5) Research on the interaction between virus and host; (6) Stem cell direction; (7) Brain science direction; (8) Experimental animal welfare ethics
.

You are welcome to actively participate in the construction of the journal column! AMEM submission website: https://mc.
manuscriptcentral.
com/amem Contact number: 010-67779337 AMEM will take the construction of first-class scientific and technological journals as the goal and the academic quality of the journals as the first lifeline, and continue to strengthen the international competitiveness and influence of the journals , to become a high-end academic exchange platform with world influence! ▼Wonderful Review of Past Issues▼AMEM Hypoxia Adaptation Column | Focus on the 2019 Nobel Prize in Physiology or Medicine for the Folic Acid-Induced Kidney Disease Animal Model | AMEM Multiple Mitochondrial Dysfunction Syndrome Complicated with Cardiomyopathy A New Rat Model | AMEMAMEM 2021 No.
4 Period online! Laboratory Animal Science and Laboratory Medicine | AMEM 2020 Highly Cited Article Highlights | AMEM Editorial Board Layout | Amanda